Activation of the mTOR signaling pathway in breast cancer MCF-7 cells by a peptide derived from Porphyra yezoensis

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 19-24

  Park, Su Jin ^a   Ryu, Jina ^a   Kim, In Hye ^a   Choi, Youn Hee ^a   Nam, Taek Jeong ^a  

^a Pukyong National University   (South Korea)

Author keywords

Apoptosis; Autophagy; MTOR; Peptide; Porphyra yezoensis; SiRNA

Indexed keywords

ALGAL PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; POLYSACCHARIDE; PORPHYRA YEZOENSIS EXTRACT; PORPHYRA YEZOENSIS PEPTIDE; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MTOR PROTEIN, HUMAN; PEPTIDE FRAGMENT; S6 KINASE; TARGET OF RAPAMYCIN KINASE; VEGETABLE PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DEGRADATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYSOSOME; MCF 7 CELL LINE; NEOPLASM; PORPHYRA; PROTEIN FUNCTION; SEAWEED; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS;

APOPTOSIS; AUTOPHAGY; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; NEOPLASM METASTASIS; NF-KAPPA B; PEPTIDE FRAGMENTS; PLANT PROTEINS; PORPHYRA; PROTO-ONCOGENE PROTEINS C-BCL-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84916215148     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3557     Document Type: Article

References (50)

1. American Cancer Society, Cancer Facts and Figures. American Cancer Society, Atlanta, GA, 2009.
2. He X, Wang Y, Zhu J, Orloff M and Eng C: Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycininduced AKT signaling. Cancer Lett 301: 168-176, 2011.
3. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
4. Pattingre S, Espert L, Biard-Piechaczyk M and Codogno P: Regulation of macroautophagy by mTOR and Beclin1 complexes. Biochimie 90: 313-323, 2008.
5. Bärlund M, Forozan F, Kononen J, et al: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92: 1252-1259, 2000.
6. Sekulic A, Hudson CC, Homme JL, et al: A direct linkage between the phosphosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60: 3504-3513, 2000.
7. Lmoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signaling. Nat Cell Biol 4: 648-657, 2002.
8. Chung J, Kuo CJ, Crabtree GR and Bieris J: Rapamycin FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69: 1227-1236, 1992.
9. Holland EC, Sonenberg N, Pandolfi PP and Thomas G: Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144, 2004.
10. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
11. Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res 256: 50-57, 2000.
12. Yin XM, Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domain of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369: 321-323, 1994.
13. Reed JC: Bcl-2 family protein: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 34: 9-19, 1997.
14. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
15. Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23: 367-387, 2004.
16. Khwaja A: Akt is more than just a Bad kinase. Nature 401: 33-34, 1999.
17. McCormick F: Cancer: survival pathways meet their end. Nature 428: 267-269, 2004.
18. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
19. Steele RJ and Lane DP: p53 in cancer: a paradigm for modern management of cancer. Surgeon 3: 197-205, 2005.
20. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Downregulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
21. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
22. Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC, Mervile MP and Bours V: Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 20: 2805-2813, 2001.
23. Heckman CA, Mehew JW and Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908, 2002.
24. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H and Troxel A: Promotion of tumorigenesis by heterozygous disruption of the beclin1 autophagy gene. J Clin Invest 112: 1809-1820, 2003.
25. Matshushita M, Suzuki NN, Obara K, Fujioka Y, Ohsumi Y and Inagaki F: Structure of Atg5.Atg16, a complex essential for autophagy. J Biol Chem 282: 6763-6772, 2007.
26. Park SJ, Ryu J, Kim IH, Choi YH and Nam TJ: Induction of apoptosis by a peptide from Porphyra yezoensis: regulation of the insulin-like growth factor I receptor signaling pathway in MCF-7 cells. Int J Oncol 45: 1011-1016, 2014.
27. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on theme. Oncogene 27: 5497-5510, 2008.
28. Xu X, Sakon M, Nagano H, Hiraoka N, et al: Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 11: 25-32, 2004.
29. Faivre S, Kroener G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688, 2006.
30. Dann SG and Thomas G: The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett 580: 2821-2829, 2006.
31. Akar U, Ozpolat B, Mehta K, et al: Targeting p70S6k prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9: 1180-1187, 2010.
32. Fesus L and Szondy Z: Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 579: 3297-3302, 2005.
33. Herman JF, Mangala LS and Mehta K: Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049-3058, 2006.
34. Fesus L and Piacentini M: Transglutaminase 2: an enigmatic enezyme with diverse function. Trends Biochem Sci 27: 534-539, 2002.
35. Malek R, Borrowicz KK, Jargiello M and Czuczwar SJ: Role of nuclear factor kappaB in the in the central nervous system. Pharmacological Rep 59: 25-33, 2007.
36. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induced release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997-5002, 1998.
37. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
38. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
39. Zhang DM, Liu JS, Deng LJ, et al: Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 34: 1331-1342, 2013.
40. Eskelinen FL: Maturation of autophagic vacuoles in Mammalian cells. Autophagy 1: 1-10, 2005.
41. Jing Ji and Zheng PS: Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 117: 103-108, 2010.
42. Cho MY, Park SY, Park S, Lee YR, Han GD and Kim JA: Geranyl derivative of phloroacetophenone induces cancer cell-specific apoptosis through Bax-mediated mitochondrial pathway in MCF-7 human breast cancer cells. Biol Pharm Bull 35: 98-104, 2012.
43. Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB: CYR61 controls p53 and NF-κB expression through PI3K/AKT/ mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 315: 86-95, 2012.
44. Klionsky DJ: The molecular machinery of autophagy: unanswered questions. J Cell Sci 118: 7-18, 2005.
45. Dumont FJ and Su Q: Mechanism of action of the immunosuppressant rapamycin. Life Sci 58: 373-395, 1996.
46. Windecker S, Roffi M and Meier B: Sirolimus eluting stent: a new era in interventional cardiology? Curr Pharm Des 9: 1077-1094, 2003.
47. Gao XM, Wong G, Wang B, et al: Inhibition of mTOR reduces chronic pressure overload cardiac hypertrophy and fibrosis. J Hypertens 24: 1663-1670, 2006.
48. Simler NR, Howell DC, Marshall RP, et al: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rat. Eur Respir J 19: 1124-1127, 2002.
49. Achenbach TV, Barrow RK and Heerneier K: Oligonucleotide-based knockdown technologies: antisense versus RNA interference. Chembiochem 4: 928-935, 2003.
50. Burnet PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Nat Acad Sci USA 95: 1432-1437, 1998.